Videos

New Treatment Option for Parkinson Disease Possible With Discovery of Enzyme

11/15/2017

The enzyme asparagine endopeptidase (AEP) has been identified as a contributor to the formation of tangles and increases in neurotoxicity among patients with Alzheimer disease and Parkinson disease (PD). In this video, Michael Banks, MD, discusses how the discovery of this enzyme's role in neurodegenerative diseases could lead to the development of AEP-inhibitors and provide new treatment options for patients with PD.

For more videos, visit The Doctor's Channel.

Migraine CME Series

Module 8 – Implementing Shared Decision-Making and Developing Personalized Treatment Plans

Module 7 – Addressing Patient Barriers in the Prevention of Chronic Migraine

Module 6 – The Role of Nonpharmacologic Treatment Approaches for the Prevention of Chronic Migraine

Module 5 – Pharmaceutical Treatments for Chronic Migraine Prophylaxis

Module 4 - New Therapeutic Targets in the Prevention of Chronic Migraine

Module 3 – Avoiding Medication Overuse Headache

Module 2 - Quality-of-Life Concerns in Patients With Migraine

Module 1 – Caring for Patients With Migraine in the COVID-19 Era: Focus on Teleneurology

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes

11/05/2024

Jolynn Tumolo ;

Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...

Patients with type 2 diabetes...

11/05/2024

Psych Congress Network

News

Alone or Together, CBT and Modafinil Improve MS-Related Fatigue

11/01/2024

Jolynn Tumolo ;

The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.

The wake-promoting drug...

11/01/2024

Neurology

News

Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy

10/28/2024

Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.

Elivaldogene autotemcel...

10/28/2024

Neurology

News

During Recovery, Stroke Patients Benefit from Supportive Social Networks

10/24/2024

Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...

Large networks of family and...

10/24/2024

Neurology

News

International Stroke Burden Saw Hike Over Last 30 Years

10/22/2024

Evi Arthur ;

International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.

International stroke burden has...

10/22/2024

Neurology

News

Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy

10/21/2024

Jolynn Tumolo ;

A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.

A lifetime history of epilepsy...

10/21/2024

Neurology

News

FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults

10/18/2024

Meagan Thistle ;

AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.

AbbVie’s VYALEV (foscarbidopa...

10/18/2024

Neurology

News

Investigational Drug Improves Motor Function in Patients With SMA

10/16/2024

Jolynn Tumolo ;

Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.

Apitegromab, an investigational...

10/16/2024

Neurology

News

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

10/15/2024

Jolynn Tumolo ;

Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...

Tolebrutinib delayed the time to...

10/15/2024

Neurology

An orange prescription container with generic pills spilling out in front of it

News

Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation

10/10/2024

Brionna Mendoza ;

A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia

A masked drug taper combined...

10/10/2024

Psych Congress Network

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

11/12/2020

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 

Emerging Treatments for Early...

11/12/2020

Neurology

Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology

11/12/2020

Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series

Early Alzheimer’s Disease...

11/12/2020

Neurology

Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

11/12/2020

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...

Emerging Treatments for Early...

11/12/2020

Neurology

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease

11/10/2020

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 

Current Treatment Limitations...

11/10/2020

Neurology

New Treatment Option for Parkinson Disease Possible With Discovery of Enzyme

Migraine CME Series

News

Alzheimer's Disease CME Series

Specialties

Events

Year Round Education

HMP Global Products